Natco Pharma shares jump 6% after Delhi HC allows firm to sell 'Risdiplam' in India

Natco Pharma share price

The shares of Natco Pharma jumped more than 6 percent on October 10 after the Delhi High Court dismissed Swiss pharma giant Roche's appeal and allowed the Indian company to sell the spinal muscular atrophy (SMA) drug Risdiplam in India.

Roche had filed an appeal at the High Court against a single-judge order passed in March 2025 that had denied an injuction on Natco's sale of the drug in India.

What had Roche appealed against?

The previous order had noted that the life-saving therapy must remain affordable and accessible. The March order had paved the way for Natco to launch the generic version of Roche's 'Risdiplam' drug.

The single judge bench had factored the challenge of invalidity of Roche's patent and laid special emphasis on the public interest, considering the Swiss company's pricing had rendered the drug inaccessible and unaffordable to the bulk of its patients, Natco said in a statement.

Natco Pharma to sell 'Risdiplam' for Rs 15,900

After the division bench of the Delhi High Court dismissed Roche's appeal, Natco said that it has decided to launch the product with immediate effect at an MRP of Rs 15,900. "The Company also intends to offer some discount to certain deserving patients through its patient access programme," it added.

Natco Pharma share price history:

Natco Pharma shares hit an intraday high at Rs 864.80 apiece during the day. The stock later pared some gains to trade 3 percent higher at around Rs 841 per share, as seen at 1.20 pm. The shares of the company have jumped more than 8 percent in the past six months, but have dropped nearly 40 percent in 2025 so far.

The stock's P/E ratio stands at 8.6. The stock is currently down 42.5 percent from its 52-week high of Rs 1,505 per share, which it had hit in December last year. The stock has however recovered around 19 percent after hitting a 52-week low of Rs 726.80 per share.

Also read: Our LIVE blog on stock market updates

Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.